Dr. Falguni Dasgupta

Editor Profile

Education / Career:

• B.Sc. (Hon)/Chemistry
• M.Sc. (Organic Chem. Spl.)
• Ph. D. (Carbohydrate Chem.)
• Post Doc.: Queen’s University, Kingston, Ontario, Canada
• Research Associate: Univ. of Wisconsin, Madison, Wisconsin, USA
• Scientist at NII, New Delhi
• Guest/Visiting Scientist, Arrhenius Lab., Univ. of Stockholm, Sweden
• Senior Scientist at Glycomed Inc., Alameda, California, USA
• Assistant Director, Medicinal Chem., NDDR, Ranbaxy Lab. Ltd., New Delhi
• Senior Director, Chemistry, Biomarin Inc., Novato, California, USA
• Founder Director, Curamyx Therapeutics (P)Ltd., New Delhi, Wellness Formulations
• Principal Scientist, ATERIS Tech. Inc., Bozeman, MT, USA, Nanotech for Diagnostics
• Co-founded Innovotech LLC., Bozeman, MT, USA…. Green Tech. Dev.
• Senior Scientist, Nanovalent Tech. Inc., Bozeman, MT, USA. Targeted Nanoparticles for Drug Delivery
• Other: Consultant, Anti-infective Design & synthesis, Microbion, Bozeman, MT, USA
• Lecturer: ACS short course on ‘Carbohydrates & Glycotehcnology’ for professionals including those from US patent & trade marks office.

Collaborative Research:

1. With National Institute of Health (NIH, USA) for the development of antigen coated nano-particular composition as vaccine against Cholera.
2. Developed new, nanoparticle coated surfaces for SPR (Surface Plasmon Resonance) instruments in collaboration with ‘Biosensing Instruments Inc., USA’.
3. Initiated collaborative research under Industry-academia Research initiative (DST), between Ranbaxy and IISc-Bangalore, RRL-Trivandrum, NCL-Pune, IICT-Hyderabad, IICB-Jadavpur, UDCT-Mumbai, IIT-Kanpur during tenure in Ranbaxy.
4. With Lawrence Berkeley Laboratory, UC Berkeley, CA, USA, to develop multivalent nanoparticles as therapeutics, under Industry-academia Research initiative (CRADA, USA).

Member:

• American Chemical Society (1984)
• Association of Carbohydrate Chemists & Technologists, India (Life Member)

Experience: R&D experience in a number of areas that included synthesis and delivery of complex organic molecules, design and synthesis of biomimetic libraries, conjugation chemistry and synthesis of targeting molecule coated microbubbles and nanoparticles for treating inflammation and delivery of anticancer compounds. Technologies involved included:

Glycotechnology: Total synthesis of complex carbohydrates and their biochemically relevant analogs for drug discovery purposes, Glycoconjugates synthesis, Protein carbohydrate conjugation chemistry.

Design and Synthesis of small libraries of Bioactive molecules: Antifungal azoles, Dipeptide mimetics as Endothelin receptor antagonists, Squalene epoxidase inhibitors containing Naphthalene core, Quinolone analogs.

Nanotechnology: Polymerized lipid nanoparticle, Synthesis of new lipid constituents for preparing novel NP constructs with specific surface chemistry, Targeted Nanoparticles for drug delivery, diagnostics as well as vaccine.

US & International Patents: 19

Selected Publication List:

Falguni Dasgupta (Author), Book title ’Bridging the Gap-Between Ayurvedic Traditions & Current Healthcare Needs’ (2023), Publisher: Walnut Publication (www.walnutpublication.com).

Falguni Dasgupta, R. Irene Masada, Philip L. Alferness, Michael Vellard, and Bill Prince, Current Org. Chemistry, 8(2004) 539-555.

F. Dasgupta, A. K. Mukherjee and N. Gangadhar, Current Medicinal Chem., 9 (2002) 549.

F. Dasgupta and R. I. Masada, Carbohydr. Res., 337 (2002) 1055-1058.

F. Dasgupta, R. I. Masada, C. M. Starr, B. Kuberan, and R. J. Linhardt, Glycoconjugate J., 17 (2001) 829-834.

R. E. Bruehl, F. Dasgupta, T. R. Katsumoto, J. H. Tan, C. R. Bertozzi*, W. Spevak, D. J. Ahn, S. D. Rosen, and J. O. Nagy, Biochem. J., 40 (2001) 5964. (*Carolyn went on to receive Nobel Prize in Chemistry in the year 2022)

F. Dasgupta, N. Gangadhar, M. Bruhaspathy, A. K. Verma, S. Sarin, and A. K. Mukherjee, Bioorg. Med. Chem. Lett., 11 (2001) 555-557.

A. K. Mukherjee and F. Dasgupta, Chemtract-Organic Chemistry, 13 (2000) 1-4.

Falguni Dasgupta, Chapter in Highthroughput Screening for Novel Anti-Inflammatories, Michael Kahn (Ed.), Birkhauser Verlag, Basel, (2000) 123-144.

W. Spevak, C. Foxall, D.H. Charych, F. Dasgupta, J.O. Nagy, J. Med. Chem., 39 (1996) 1018.

W. Spevak, F. Dasgupta, C, J, Hobbs and J. O. Nagy, J. Org. Chem., 61 (1996) 3417.

F. Dasgupta and Per J. Garegg, Synthesis, (1994) 1121-1123.

F. Dasgupta and L. Anderson, Carbohydr. Res., 264 (1994) 155-160.

J. H. Musser, B. N. N. Rao, M. Nashed, F. Dasgupta, S. Abbas, A. Nematalla, V. Date, C. Foxall, D. Tyrell, and B. K. Brandley, in Trends in Drug Res., V. Classen (Ed), Elsevier Press, Amsterdam, (1993) 33-40.

F. Dasgupta, B. N. N. Rao, Expert Opinion in Investigational Drugs, 3 (1994) 709.

B. K. Brandley, N. Rao, M. A. Nashed, F. Dasgupta, S. A. Abbas, D. Asa, T. Gant, and J. Musser, in C. G. Gahmberg, T. Maundrup-Poulsen, L. Wogensen Bach, B. Hokfelt (Eds), Elsevier Science Publishers, (1992) 99-111.

D. Tyrell, P. James, N. Rao, C. Foxall, S. Abbas, F. Dasgupta, M. Nashed, A. Hasegawa, M. Kiso, D. Asa, J. Kidd, and B. K. Brandley, Proc. Natl. Acad. Sci., USA, 88 (1991) 10372-10376.

F. Dasgupta and L. Anderson, Carbohydr. Res., 202 (1990) 239-255.

F. Dasgupta and Per. J. Garegg, Carbohydr. Res., 202 (1990) 225-238.

F. Dasgupta and Per. J. Garegg, J. Chem. Commun., (1989) 1640-1641.

F. Dasgupta and Per. J. Garegg, Acta Chem Scand., 43 (1989) 471-475.

F. Dasgupta and Per J. Garegg, Carbohydr. Res., 177 (1988) C13.

F. Dasgupta and Per. J. Garegg, J. Carbohydr. Chem., 7 (1988) 701- 707.

F. Dasgupta and Per. J. Garegg, Synthesis, (1988) 626-628.